IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+2.33%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$903M
AUM Growth
+$903M
(-20%)
Cap. Flow
-$189M
Cap. Flow
% of AUM
-20.9%
Top 10 Holdings %
Top 10 Hldgs %
48.7%
Holding
109
New
26
Increased
18
Reduced
25
Closed
31
Top Buys
| 1 |
Elevance Health
ELV
|
$28.3M |
| 2 |
Novartis
NVS
|
$27.9M |
| 3 |
Mineralys Therapeutics
MLYS
|
$22.6M |
| 4 |
Baxter International
BAX
|
$17.1M |
| 5 |
Ascendis Pharma
ASND
|
$15.6M |
Top Sells
| 1 |
Centene
CNC
|
$30.3M |
| 2 |
Cardinal Health
CAH
|
$29.6M |
| 3 |
Eli Lilly
LLY
|
$29.3M |
| 4 |
Intuitive Surgical
ISRG
|
$20.9M |
| 5 |
CVS Health
CVS
|
$20.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Becton Dickinson
BDX
$53.4B
| $4.58M | 0.49% |
+20,000
| New | +$4.58M |
|
52
Biohaven
BHVN
$1.68B
| $4.21M | 0.45% |
+175,000
| New | +$4.21M |
|
53
Crinetics Pharmaceuticals
CRNX
$3.2B
| $4.19M | 0.45% |
125,000
-175,000
| -58% | -$5.87M |
|
54
Scholar Rock
SRRK
$3.32B
| $4.02M | 0.43% |
125,000
-250,000
| -67% | -$8.04M |
|
55
Alignment Healthcare
ALHC
$3.27B
| $3.72M | 0.4% |
200,000
-300,000
| -60% | -$5.59M |
|
56
Globus Medical
GMED
$7.95B
| $3.66M | 0.39% |
+50,000
| New | +$3.66M |
|
57
BioNTech
BNTX
$24.1B
| $3.64M | 0.39% |
40,000
-60,000
| -60% | -$5.46M |
|
58
Catalyst Pharmaceutical
CPRX
$2.44B
| $3.64M | 0.39% |
150,000
-150,000
| -50% | -$3.64M |
|
59
BridgeBio Pharma
BBIO
$9.9B
| $3.46M | 0.37% |
+100,000
| New | +$3.46M |
|
60
Sana Biotechnology
SANA
$726M
| $3.36M | 0.36% |
2,000,000
| – | – |
|
61
Cigna
CI
$79.8B
| $3.29M | 0.35% |
+10,000
| New | +$3.29M |
|
62
Nurix Therapeutics
NRIX
$703M
| $3.27M | 0.35% |
275,000
+25,000
| +10% | +$297K |
|
63
Verastem
VSTM
$565M
| $3.02M | 0.32% |
+500,000
| New | +$3.02M |
|
64
Oscar Health
OSCR
$4.54B
| $2.62M | 0.28% |
200,000
-500,000
| -71% | -$6.56M |
|
65
Repligen
RGEN
$6.64B
| $2.54M | 0.27% |
20,000
-20,000
| -50% | -$2.54M |
|
66
Jasper Therapeutics
JSPR
$44.9M
| $2.47M | 0.26% |
575,000
-75,000
| -12% | -$323K |
|
67
Arrowhead Research
ARWR
$3.72B
| $2.23M | 0.24% |
175,000
-100,000
| -36% | -$1.27M |
|
|
ATYR
68
aTyr Pharma
ATYR
$569M
| $2.11M | 0.22% |
700,000
+325,000
| +87% | +$982K |
|
69
Terns Pharmaceuticals
TERN
$642M
| $1.93M | 0.21% |
700,000
+250,000
| +56% | +$690K |
|
|
MREO
70
Mereo BioPharma
MREO
$277M
| $1.8M | 0.19% |
800,000
-200,000
| -20% | -$450K |
|
71
Rezolute
RZLT
$623M
| $1.45M | 0.15% |
500,000
| – | – |
|
72
Cabaletta Bio
CABA
$137M
| $1.18M | 0.13% |
850,000
+350,000
| +70% | +$485K |
|
73
Tenax Therapeutics
TENX
$27.3M
| $1.09M | 0.12% |
+167,000
| New | +$1.09M |
|
74
Alto Neuroscience
ANRO
$101M
| $864K | 0.09% |
400,000
+100,000
| +33% | +$216K |
|
|
PTN
75
DELISTED
Palatin Technologies
PTN
| $583K | 0.06% |
+1,000,000
| New | +$583K |
|